Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-Versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Alemtuzumab; Ciclosporin; Ciclosporin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Filgrastim; Fludarabine; Methotrexate; Prednisone; Rituximab; Sirolimus; Tacrolimus; Tacrolimus; Vincristine
- Indications Acute myeloid leukaemia; B-cell prolymphocytic leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Essential thrombocythaemia; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell prolymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2019 Biomarkers information updated
- 30 Jun 2010 Planned end date (1 Jun 2016) added as reported by ClinicalTrials.gov.
- 01 May 2009 Planned number of patients changed from 20 to 85 as reported by ClinicalTrials.gov.